SERPINF1 and Miyoshi myopathy: PEDF, together with vascular cell adhesion molecule 1 (VCAM1) and hepatocyte growth factor activator (HGFA), were identified as promising biomarkers for extramedullary MM (EMM), demonstrating reasonable accuracy in distinguishing EMM patients from MM patients [85].